Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 975 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intensive therapy Clear all
Completed Phase 2 Interventional Results available

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02807558
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Tamibarotene, Azacitidine, Daratumumab
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
Hartford, Connecticut • Miami, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Dose Optimization for Stroke Evaluation

NCT01749358
View directory record Official record
Conditions
Stroke, Cerebrovascular Disorders, Brain Ischemia, Infarction
Interventions
Accelerated Skill Acquisition Program (ASAP), Active Monitoring
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit

NCT02056119
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Vibrating Mesh Nebulizer Arm, Jet Nebulizer Arm
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
1 Year and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 25, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Teachers Leading the Front Lines - North Carolina (Tealeaf-NC)

NCT06587230
View directory record Official record
Conditions
Child Behavior, Mental Health Issue, Psychosocial Functioning, Depression, Anxiety
Interventions
Teachers Leading the Frontlines, Responding to Students' Emotions Through Education
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 99 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

NCT02967432
View directory record Official record
Conditions
Staphylococcus
Interventions
Mupirocin Topical Ointment, Petroleum Jelly
Drug
Lead sponsor
Crouse Hospital
Other
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients

NCT01831999
View directory record Official record
Conditions
Substance-Related Disorders, Mental Disorders
Interventions
RecoveryTrack - Extended Care (RT-E)
Behavioral
Lead sponsor
Treatment Research Institute
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Collingswood, New Jersey • Marlton, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis

NCT03094364
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Hemiparesis
Interventions
Gaming CI Therapy
Behavioral
Lead sponsor
University of Massachusetts, Lowell
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 25, 2026, 9:02 PM EDT
Terminated Phase 3 Interventional

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

NCT00307099
View directory record Official record
Conditions
Bacterial Infection
Interventions
Meropenem, Standard antibiotic therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

NCT02347098
View directory record Official record
Conditions
Acute Coronary Artery Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00049569
View directory record Official record
Conditions
L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
cytarabine, methotrexate, vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, imatinib mesylate, cyclophosphamide, etoposide, filgrastim, leucovorin calcium, asparaginase, therapeutic hydrocortisone
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 25, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Evaluating Additive Effects of Including Canines in Regulating Together

NCT05803343
View directory record Official record
Conditions
Autism Spectrum Disorder, Emotion Regulation
Interventions
Regulating Together-Canine, Regulating Together-Standard
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 15 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 9:02 PM EDT
Withdrawn Phase 4 Interventional

Adaptive Response to Intervention (RTI) for Students With ADHD

NCT03511976
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)

NCT00790517
View directory record Official record
Conditions
Weight Loss, Diabetes Mellitus, Type 2, Psychotic Disorders
Interventions
Premier Lifestyle Intervention with DASH Diet
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 9:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study

NCT04474834
View directory record Official record
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
737 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Automated Screening Device to Detect MTMROP

NCT06517836
View directory record Official record
Conditions
Retinopathy of Prematurity, ROP
Interventions
iROP DL
Device
Lead sponsor
Siloam Vision
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
1,284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01546038
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
PF-04449913, Low dose ARA-C (LDAC), Decitabine, Daunorubicin, Cytarabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trauma Management Therapy for OEF and OIF Combat Veterans

NCT02809326
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Combat Disorders
Interventions
17 week Exposure Therapy Control Arm, Trauma Management Therapy, Intensive 3-Week Trauma Management Therapy
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 25, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors

NCT06124508
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Lung Cancer Screening Education, Semi-Structured Interview, Standard of Care Lung Cancer Screening Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

NCT00695084
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Constraint-Induced Movement Therapy
Behavioral
Lead sponsor
National Multiple Sclerosis Society
Other
Eligibility
21 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2008 · Synced Oct 25, 2026, 9:02 PM EDT
Withdrawn Phase 2 Interventional

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

NCT05766514
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Cladribine, Cytarabine, Decitabine, azacitidine or decitabine, Venetoclax
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 25, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

The Youth Opioid Recovery Support (YORS) Intervention

NCT04173416
View directory record Official record
Conditions
Opioid-use Disorder, Medication Adherence
Interventions
Youth Opioid Recovery Support (YORS)
Behavioral
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years to 28 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

NCT04480424
View directory record Official record
Conditions
COVID-19
Interventions
GAMUNEX-C, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 25, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 25, 2026, 9:02 PM EDT